Hot AI Mandate: Strategic Fund of Big Pharma Focuses on Bioelectronic Medicine

28 Sep

An evergreen strategic venture capital fund of big pharma closed at $100 million in 2013, and is managed by a small, dedicated team based in Massachusetts and California. The fund focuses on investments in companies developing pioneering bioelectronic medicines/ neuromodulation device and related enabling technologies. The initial investments are typically ranging from $5-$7 million in Series A, and the fund will also consider follow-on investments. The firm looks for investment opportunities globally.

The firm is dedicated to advancing bioelectronic medicines and is looking to invest in high-return opportunities in three areas: (1) Teams pursuing new therapies for existing peripheral neurostimulation devices. (2) Teams developing novel bioelectronic medicine technologies for existing neurostimulation therapies. (3) Companies introducing advanced technologies that are enabling for bioelectronics medicines. The firm is particularly interested in improved neural interfaces, novel power sources and wireless powering technology, ultra-low power chip architectures, sensors that can close-the-loop for adaptive therapies and new implantation and imaging methods. The firm is stage agnostic.

The firm typically will take board of directors or board observer seat, but it is not necessary. The fund exclusively invests in privately-held companies and primarily in pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: